膜反应性溶解抑制因子在非小细胞肺癌中的表达及其临床意义

Expression of membrane inhibitor of reactive lysis in non-small cell lung carcinoma and its clinical significance

目的观察膜反应性溶解抑制因子（MIRL，CD59）在非小细胞肺癌（NSCLC）中的表达，分析其表达与临床分期、化疗用药及预后的关系。方法免疫组织化学法检测8例NSCLC癌旁组织和36例NSCLC手术标本中MIRL的表达，分析临床资料。结果36例NSCLC标本中，共有10例（27．8％）表达MIRL，其中18例肺鳞癌中有4例（22．2％）表达，而16例肺腺癌中有6例（37．5％）表达，两者差异有统计学意义（P〉0．05），而2例大细胞肺癌不表达；MIRL的表达与无病生存期无相关关系（P〉0．05）；术前行新辅助化疗的患者的MIRL表达率低于未行新辅助化疗组（P〈0．05）。结论NSCLC中有MIRL的表达，提示在NSCLC抗体治疗中应同时阻断MIRL的免疫抑制效应。

Objective To survey membrane inhibitor of reactive lysis（MIRL） expression in non-small cell lung carcinoma（NSCLC） and to analyze the relationship between MIRL expression and clinical staging, adjuvant chemotherapy and disease-free survial. Methods The expression of MIRL in 8 adjacent tissues and 36 NSCLC sam- ples were determined by immunohistochemistry. Furthermore, the relationship between MIRL expression and clinical stage, adjuvant chemotherapy and disease-free survival was assayed by follow-up. Results Among 36 samples of non- small-cell lung cancer,there were 10（27.8% ） samples expiessing MIRL. Out of 18 samples of squamous carcinoma, 4 （22.2%） expressed MIRL, while 6 （37.5 % ） expressed it in 16 samples of adenocarcinoma, there was no statistical significance between them（P 〉0. 05）. There were no expression in 2 samples of large cell carcinoma. There was no correlation between MIRL expression and disease-free survival（ P 〉 0. 05 ）. MIRL positive expression rate in patients with preoperational adjuvant chemotherapy was sign/ficantly lower than that of those without preopemtional adjuvant chemotherapy（P 〈 0. 05）. Conclusions There is great percentage of MIRL expression in NSCLC. Our present study suggests that the immunological inhibition of MIRL should be blocked when monoclonal antibody is used in the treatment of NSCLC.